

BC PHARMACARE NEWSLETTER

Edition 20-010

May 26, 2020



In this edition

HIGH-COST DRUGS.....	1
BENEFITS	1
YOUR VOICE: PATIENT INPUT NEEDED FOR DRUG DECISIONS.....	2

HIGH-COST DRUGS

The following [high-cost drug](#) has been approved for a line extension under the DINs below:

COVERAGE EFFECTIVE	May 26, 2020				
DRUG NAME	mepolizumab (Nucala™)				
INDICATION	eosinophilic asthma				
DIN	02492989	STRENGTH/Form	Pre-filled autoinjector	ALLOWABLE MARKUP	5%
	02492997		Pre-filled safety syringe		

BENEFITS

The following device has been added as a PharmaCare benefit and is now listed under [Insulin Pump PINs](#):

COVERAGE EFFECTIVE	May 19, 2020		
DEVICE	MiniMed 670G	DIN	45230015

The PharmaCare Newsletter is published by the Pharmaceutical Services Division to provide information to British Columbia's health care providers.

The use of PharmaNet is not intended as a substitute for professional judgment. Information on PharmaNet is not exhaustive and cannot be relied upon as complete. The absence of a warning about a drug or drug combination is not an indication that the drug or drug combination is safe, appropriate or effective in any given patient. Health care professionals should confirm information obtained from PharmaNet, and ensure no additional relevant information exists, before making patient care decisions.

www.gov.bc.ca/pharmacarepharmacists | www.gov.bc.ca/pharmacareprescribers | www.gov.bc.ca/pharmacaredeviceproviders



YOUR VOICE: PATIENT INPUT NEEDED FOR DRUG DECISIONS

The feedback and experiences of patients, caregivers, and patient groups is integral to [B.C.'s drug review process](#).

The Ministry depends on pharmacies and practitioners to help connect patients and caregivers with opportunities to provide input. If you have a patient who is currently taking one of the drugs under review or who has the condition the new drug treats, please encourage them to visit www.gov.bc.ca/BCyourvoice.

DRUG	halobetasol propionate and tazarotene (Duobrii®)
INDICATION	Treatment of moderate to severe plaque psoriasis
INPUT WINDOW	May 20–June 17, 2020

DRUG	esketamine hydrochloride (Spravato™)
INDICATION	Major depressive disorder in adults
INPUT WINDOW	May 20–June 17, 2020